Epizyme, Inc. (NASDAQ:EPZM) has been given an average rating of “Buy” by the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $15.00.
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley downgraded shares of Epizyme from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $10.00 to $5.00 in a research note on Monday, August 9th. HC Wainwright dropped their price objective on shares of Epizyme from $36.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, August 10th.
A number of institutional investors have recently added to or reduced their stakes in EPZM. Hood River Capital Management LLC bought a new position in Epizyme during the 2nd quarter worth approximately $7,096,000. BlackRock Inc. raised its holdings in Epizyme by 6.1% during the 1st quarter. BlackRock Inc. now owns 8,392,058 shares of the biopharmaceutical company’s stock worth $73,094,000 after purchasing an additional 481,030 shares during the last quarter. Woodline Partners LP bought a new position in Epizyme during the 2nd quarter worth approximately $3,368,000. Millennium Management LLC raised its holdings in Epizyme by 175.1% during the 1st quarter. Millennium Management LLC now owns 591,297 shares of the biopharmaceutical company’s stock worth $5,150,000 after purchasing an additional 376,331 shares during the last quarter. Finally, Wellington Shields Capital Management LLC bought a new position in Epizyme during the 1st quarter worth approximately $3,237,000. Hedge funds and other institutional investors own 92.26% of the company’s stock.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Monday, August 9th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.03). Epizyme had a negative net margin of 788.60% and a negative return on equity of 216.16%. The business had revenue of $13.01 million during the quarter, compared to analyst estimates of $8.99 million. During the same quarter last year, the company posted ($0.58) earnings per share. The company’s revenue was up 427.4% on a year-over-year basis. On average, equities analysts expect that Epizyme will post -2.15 EPS for the current fiscal year.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer.
Read More: Understanding the different types of bonds
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.